- Conditions
- Cystic Fibrosis
- Interventions
- Lenabasum 20 mg, Lenabasum 5 mg, Placebo
- Drug · Other
- Lead sponsor
- Corbus Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 447 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 30 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2089–2112
of 7,464
matching trials from the live ClinicalTrials.gov search.
- Conditions
- FSGS
- Interventions
- DMX-200, Placebo
- Drug
- Lead sponsor
- Dimerix Bioscience Pty Ltd
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 44 more
- Conditions
- Menopause, Estrogen Deficiency, Women, Aging
- Interventions
- GnRH antagonist
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Migraine
- Interventions
- Galcanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 862 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 80
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Carmichael, California + 72 more
- Conditions
- Influenza
- Interventions
- DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra)
- Drug
- Lead sponsor
- Ansun Biopharma, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 42
- States / cities
- Carmichael, California • Chula Vista, California • La Mesa, California + 39 more
- Conditions
- Advanced Cancer
- Interventions
- PF-05212384, PD-0325901, irinotecan
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Santa Monica, California • Aurora, Colorado + 3 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 70
- States / cities
- Little Rock, Arkansas • Concord, California • Encino, California + 60 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Aclidinium bromide, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 90 more
- Conditions
- Cystic Fibrosis
- Interventions
- PTI-428, Placebo
- Drug
- Lead sponsor
- Proteostasis Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Stanford, California + 21 more
- Conditions
- Atopic Dermatitis (AD), Non-atopic Healthy Controls
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- TRAIL-R1 mAb (TRM-1;HGS-ETR1)
- Drug
- Lead sponsor
- Human Genome Sciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Chicago, Illinois • Durham, North Carolina + 2 more
- Conditions
- Binge Eating Disorder
- Interventions
- Dasotraline
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 56 Years
- Enrollment
- 533 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 57
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Encino, California + 52 more
- Conditions
- ADPKD, Autosomal Dominant Polycystic Kidney
- Interventions
- Pravastatin, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 25 Years to 60 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Amivantamab, Pembrolizumab, Paclitaxel, Carboplatin
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 15
- States / cities
- La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- Placebo, Cenicriviroc
- Drug
- Lead sponsor
- Tobira Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,778 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 204
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 144 more
- Conditions
- Exercise-induced Bronchospasm
- Interventions
- albuterol aerosol by HFA MDI, albuterol aerosol by HFA BOI, placebo aerosol by HFA
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Englewood, Colorado • Lakewood, Colorado
- Conditions
- Micronutrient Deficiencies
- Interventions
- MNP + Zn/Fe, MNP + Zn, Placebo
- Dietary Supplement
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 5 Months to 10 Months
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Multiple Myeloma
- Interventions
- IGM-2644
- Drug
- Lead sponsor
- IGM Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 5
- States / cities
- Duarte, California • Denver, Colorado • New York, New York + 2 more
- Conditions
- Obesity, Overweight, Children
- Interventions
- Patient navigation
- Behavioral
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 2 Years to 6 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Lung Cancer
- Interventions
- cisplatin, docetaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 97
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
- Conditions
- AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- CER-1236, Cyclophosphamide, Fludarabine, Mesna
- Drug
- Lead sponsor
- CERo Therapeutics Holdings, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 5
- States / cities
- Sacramento, California • Denver, Colorado • Nashville, Tennessee + 2 more
- Conditions
- BRAF V600E-mutant Metastatic Colorectal Cancer
- Interventions
- Encorafenib, Binimetinib, Cetuximab, Irinotecan, Folinic Acid, 5-Fluorouracil
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 702 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 90
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 45 more
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 3,882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
- Conditions
- Leukemia
- Interventions
- sargramostim, busulfan, cyclophosphamide, cytarabine, gemtuzumab ozogamicin (GO), Daunorubicin, Autologous HCT, Allogeneic HCT
- Biological · Drug · Procedure
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 16 Years to 60 Years
- Enrollment
- 657 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2019
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 69 more